TY  - JOUR
AU  - Tzaridis, Theophilos
AU  - Milde, Till
AU  - Pajtler, Kristian
AU  - Bender, Sebastian
AU  - Jones, David
AU  - Müller, Simone
AU  - Wittmann, Andrea
AU  - Schlotter, Magdalena
AU  - Kulozik, Andreas E
AU  - Lichter, Peter
AU  - Peter Collins, V.
AU  - Witt, Olaf
AU  - Kool, Marcel
AU  - Korshunov, Andrey
AU  - Pfister, Stefan
AU  - Witt, Hendrik
TI  - Low-dose Actinomycin-D treatment re-establishes the tumoursuppressive function of P53 in RELA-positive ependymoma.
JO  - OncoTarget
VL  - 7
IS  - 38
SN  - 1949-2553
CY  - [S.l.]
PB  - Impact Journals LLC
M1  - DKFZ-2017-05771
SP  - 61860 - 61873
PY  - 2016
AB  - Ependymomas in children can arise throughout all compartments of the central nervous system (CNS). Highly malignant paediatric ependymoma subtypes are Group A tumours of the posterior fossa (PF-EPN-A) and RELA-fusion positive (ST-EPN-RELA) tumours in the supratentorial compartment. It was repeatedly reported in smaller series that accumulation of p53 is frequently observed in ependymomas and that immunohistochemical staining correlates with poor clinical outcome, while TP53 mutations are rare. Our TP53 mutation analysis of 130 primary ependymomas identified a mutation rate of only 3
LB  - PUB:(DE-HGF)16
C6  - pmid:27556362
C2  - pmc:PMC5308696
DO  - DOI:10.18632/oncotarget.11452
UR  - https://inrepo02.dkfz.de/record/130693
ER  -